Rajiv Dhand, MD
Pulmonary Disease · Knoxville, TNNPI 1538118872
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Boehringer Ingelheim at 35.2% of the total. Reporting peaked in 2019 at $61,367 and has fallen 87.9% since, to $7,404 in 2025. Among pulmonary disease clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 397 payments — averaging $241.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$34K
- Mylan Specialty L.p.$18K
- Astrazeneca UK Limited$14K
- AstraZeneca$8K
- Genentech USA, Inc.$7K
- Teva Pharmaceuticals USA, Inc.$6K
- plus $10K from 40 others
Across 21 payments — averaging $21,850 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mylan Specialty L.p.$459K
What the payments were for
- Consulting fees$47,93650%
- Speaking & faculty fees$25,07026%
- Travel & lodging$14,58015%
- Food & beverage$8,1449%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SPIRIVA$15,143
- BEVESPI AEROSPHERE$13,447
- Yupelri$13,050
- STIOLTO RESPIMAT$8,249
- STIOLTO$3,364
- ProAir Digihaler$1,940
- SPIRIVA RESPIMAT$1,318
- ArmonAir Digihaler$940
- AirDuo RespiClick$940
- BREZTRI AEROSPHERE$778
How this compares
$95,750 in reported general payments places this provider in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prolastin CAlpha-1-Proteinase Inhibitor | 14 | $129,851 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $62,793 |
| Spiriva RespimatTiotropium Bromide | 46 | $45,825 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 64 | $44,043 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $27,314 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $18,473 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $13,541 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 27 | $9,770 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,351 |
| Advair HfaFluticasone Propion/Salmeterol | 30 | $8,415 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,793 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 77 | $1,980 |
| Fluticasone Propionate | 43 | $722 |
| Azelastine Hcl | 13 | $653 |
| Roflumilast | 11 | $400 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCProlastin C | $213 | $129,85114 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $33,706 | $89,868110 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $1,007 | $85,68489 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $7,702 | $45,78696 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 339 pulmonary disease providers in Tennessee.
Other pulmonary disease in Knoxville
- John SwisherKnoxville$234K
- John PrinceKnoxville$117K
- Varun ShahKnoxville$64K
- Benjamin BevillKnoxville$31K
- Shannon ByrdKnoxville$23K
- James PharaohKnoxville$20K
- Isaac BineyKnoxville$16K
- Lisa LancasterNashville$519K
- Krishnendu BhadraChattanooga$494K
- Aaron MilstoneFranklin$482K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.